Stewart takes responsibility for maximising the value of Amarin’s lead product, AMR101, a new drug currently in Phase 3 clinical trials for the treatment of high triglycerides. The company has also completed enrolment to its Phase 3 Marine trial earlier than expected, with results now due early next year.
Stewart has more than 30 years of experience in the pharmaceutical industry, including five as ceo of CollaGenex Pharmaceuticals. He also worked for the ASTA Medica Group, where for 10 years he managed several business units in the US and internationally. He began his career in sales and marketing for Winthrop Laboratories, in the UK, and subsequently held a number of positions of increasing responsibility within the Sterling-Winthrop Group.
Declan Doogan, who has been the company’s interim ceo, will continue to support Amarin as chief medical officer for the majority of his time.
Amarin names Colin Stewart as president and ceo
Has been in the pharmaceutical industry for more than 30 years
You may also like
Research & Development
Nuclera and University of Cambridge researchers demonstrate rapid structural analysis of challenging drug target
Collaboration combines cell-free protein synthesis, proprietary nanodisc technology and cryo-electron microscopy (cryo-EM) for high-resolution structural analysis of a G protein-coupled receptor (GPCR)
Cleaning
Guardtech partner with Intense Pulsed Light innovators Biopulz to offer game-changing new cleanroom decontamination solution
New partnership will give Guardtech clients access to Biopulz’s mobile Eloane tower and integrated E-z̈o IPL decontamination system as part of their cleanroom installation projects
Research & Development
Evotec secures $2.9m grant to advance stem cell-based drug safety testing
The three-year Gates Foundation grant will support Evotec's human induced pluripotent stem cell platform, helping global health researchers identify potential developmental toxicity risks earlier in drug discovery
Regulatory
FDA rejects Summit Therapeutics’ ivonescimab lung cancer drug
The US regulator has issued a complete response letter for the PD-1/VEGF bispecific antibody, citing a lack of statistically significant overall survival benefit in a Phase III trial despite improvements in progression-free survival